Spots Global Cancer Trial Database for immune checkpoint inhibitor
Every month we try and update this database with for immune checkpoint inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | NCT06142617 | Non Small Cell ... Immune Checkpoi... EGFR Exon 21 Mu... | Pembrolizumab, ... Osimertinib | 18 Years - | Peking Union Medical College Hospital | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas | NCT03925246 | High Grade Glio... Brain Cancer | Nivolumab | 18 Years - 85 Years | Assistance Publique - Hôpitaux de Paris | |
| Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma | NCT03984357 | Nasopharyngeal ... | PD-1 blocking a... Gemcitabine Cisplatin Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | NCT02973789 | Nonsmall Cell L... NSCLC | NovoTTF-200T Immune checkpoi... | 22 Years - | NovoCure Ltd. | |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors | NCT05915481 | Advanced Solid ... Stereotactic Bo... Immune Checkpoi... Safety Efficacy | Cadonilimab Stereotactic bo... | 18 Years - 75 Years | Peking University Third Hospital | |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | NCT05846659 | Oligoprogressiv... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. | NCT03666273 | Advanced Solid ... Head and Neck S... | Bapotulimab (BA... Bapotulimab (BA... | 18 Years - | Bayer | |
| Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | NCT06074029 | Biliary Tract C... Immune Checkpoi... Predictive Canc... | Immune Checkpoi... | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma | NCT03984357 | Nasopharyngeal ... | PD-1 blocking a... Gemcitabine Cisplatin Intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma | NCT04965454 | Hepatocellular ... | Fluorine-18 flu... | 18 Years - | Queen's Medical Center | |
| Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC | NCT04867330 | Oropharyngeal C... Immune Checkpoi... De-escalation | Toxicities redu... | 18 Years - | Fudan University | |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | NCT05846646 | Oligometastatic... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | NCT05311566 | Cervical Carcin... Chemoradiothera... Anti-programmed... Immunotherapy Immune Checkpoi... Survival Outcom... Adverse Events Early Stage Cer... Locally Advance... | Camrelizumab pl... | 18 Years - | Peking Union Medical College Hospital | |
| Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection | NCT05913583 | Graft Rejection Hepatocellular ... Immunotherapy Immune Checkpoi... | Immune checkpoi... | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients | NCT04473703 | Adverse Reactio... Immune Checkpoi... Non-Small Cell ... Cardiac Event | renin-angiotens... | 18 Years - 80 Years | Shanghai Chest Hospital | |
| A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | NCT06255223 | Renal Cell Carc... Radiotherapy Immune Checkpoi... | High-dose Radio... Low-dose Radiot... Anti-PD-1 monoc... | 18 Years - 80 Years | Jinling Hospital, China | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma | NCT04965454 | Hepatocellular ... | Fluorine-18 flu... | 18 Years - | Queen's Medical Center | |
| The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors | NCT04038996 | Cancer | 18 Years - 99 Years | University of Freiburg | ||
| DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | NCT04334759 | Mesothelioma Pleural Mesothe... Malignant Pleur... | Durvalumab Standard Chemot... Ipilimumab and ... | 18 Years - | PrECOG, LLC. | |
| Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors | NCT05653531 | Immune Checkpoi... Lung Cancer Liver Biomarker... Transaminases | Blood sample | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| Thyroid Dysfunction and Nivolumab Reponse in NSCLC | NCT04470440 | Non Small Cell ... Treatment Adver... Thyroid Dysfunc... Immune Checkpoi... Prognosis | 18 Years - | University Hospital, Brest | ||
| Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation | NCT05910970 | Hepatocellular ... Recurrence Immune Checkpoi... | Adjuvant tislel... Adjuvant tislel... | 18 Years - 70 Years | Guangxi Medical University | |
| Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer | NCT04913311 | Lung Non-Small ... | Biospecimen Col... Bronchoscopy wi... Chemoradiothera... Computed Tomogr... Diagnostic Labo... Immune Checkpoi... Nasal Wash and ... Quality-of-Life... Questionnaire A... Spirometry | - | M.D. Anderson Cancer Center | |
| IC Plus Low-dose Radiation Plus Cadonilimab in LANPC | NCT05941741 | Nasopharyngeal ... Immune Checkpoi... Radiotherapy Chemotherapy | Intensity Modul... Chemotherapy Immune checkpoi... Low-dose radiot... | 18 Years - 70 Years | Sun Yat-sen University | |
| QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management | NCT05626764 | Solid Tumor Hematologic Can... | QoL & irAEs det... QoL & irAEs det... | 18 Years - | Hospices Civils de Lyon | |
| Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours | NCT06022692 | Gastrointestina... | Water-filtered ... tislelizumab (B... | 18 Years - 75 Years | Zhejiang Hospital | |
| Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | NCT04541251 | Lung Cancer, No... Artificial Inte... | Camrelizumab + ... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| The Gut Immune System During Immune Checkpoint Inhibitor Therapy | NCT04600180 | Cancer | sigmoidoscopies... | 18 Years - | University Medical Center Groningen | |
| Biomarkers in Immunotherapy of Melanoma | NCT05878977 | Metastatic Mela... Immune Checkpoi... Gastrointestina... Exosomal mRNA E... | Immune checkpoi... | 18 Years - | Institute of Oncology Ljubljana | |
| Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy | NCT03817736 | HCC | TACE SBRT Immune Checkpoi... | 18 Years - 75 Years | The University of Hong Kong | |
| Cancer Panel From Blood of Lung Cancer Patients | NCT03235765 | Non Small Cell ... Non Small Cell ... | MACROGEN Pan Ca... | 20 Years - | Seoul National University Hospital | |
| Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer | NCT05285579 | Renal Cell Carc... Renal Cancer Renal Cancer Me... | Blood collectio... Tumour samples | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | NCT04954599 | Unspecified Adu... | CP-506 Carboplatin Immune checkpoi... | 18 Years - | Maastricht University Medical Center | |
| Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer | NCT05269485 | Toxicity Due to... Non-small Cell ... | High-dose fract... Low-dose fracti... | 18 Years - 70 Years | Anhui Provincial Hospital | |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | NCT02973789 | Nonsmall Cell L... NSCLC | NovoTTF-200T Immune checkpoi... | 22 Years - | NovoCure Ltd. | |
| Electroporation Potentiated Immunotherapy in Cancer | NCT04835402 | Pancreas Cancer... | Pembrolizumab Irreversible el... | 18 Years - | Aalborg University Hospital | |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | NCT05335928 | Myocarditis Acu... Cancer | Abatacept plus Placebo | 18 Years - | Massachusetts General Hospital | |
| Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) | NCT04968106 | Resectable Sarc... | Doxorubicin Ifosfamide INCMGA00012 | 18 Years - | Institut Bergonié | |
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | NCT05848011 | Androgen-Indepe... Androgen-Indepe... Prostate Cancer... Androgen-Insens... Androgen-Resist... Hormone Refract... Immunotherapy Immune Checkpoi... Inhibitory Chec... | lorigerlimab docetaxel Prednisone | 18 Years - | MacroGenics | |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NCT05877430 | NSCLC HNSCC Melanoma Metastatic Canc... Advanced Solid ... Advanced Cancer | CJRB-101 Pembrolizumab i... | 18 Years - | CJ Bioscience, Inc. | |
| Toripalimab Plus FLOT in Locally Advanced Gastric Cancer | NCT04891016 | Chemotherapy Immune Checkpoi... Locally Advance... | delayed toripal... control | 18 Years - 70 Years | Henan Cancer Hospital | |
| A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial | NCT06026254 | Solid Tumor, Ad... | IMSA101 Immune Checkpoi... | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | NCT04137588 | Advanced Non-sq... | Antiangiogenesi... Immune checkpoi... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | NCT05007613 | Esophageal Canc... Metastatic Canc... Squamous Cell C... | Cabozantinib 40... Atezolizumab In... | 20 Years - | National Taiwan University Hospital | |
| Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC | NCT05754203 | Lung Cancer Immune Checkpoi... Radiotherapy | Super-hyperfrac... | 18 Years - 75 Years | Xinqiao Hospital of Chongqing | |
| Chemotherapy With or Without Checkpoint Inhibitors for Lung Cancer | NCT05059951 | Non Small Cell ... | Immune checkpoi... | 18 Years - | Hunan Province Tumor Hospital | |
| The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors | NCT04038996 | Cancer | 18 Years - 99 Years | University of Freiburg | ||
| A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC | NCT04167774 | Non-Small Cell ... | Camrelizumab nb-Paclitaxel | 18 Years - | Sun Yat-sen University | |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis | NCT06096779 | Hepatocellular ... | Atezolizumab Bevacizumab | 18 Years - | Genentech, Inc. | |
| Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction | NCT03492242 | Arthritis Cancer Cardiac Disease Endocrine Syste... Autoimmune Dise... Ophthalmopathy Myositis Neuropathy | Immune checkpoi... | 18 Years - | Groupe Hospitalier Pitie-Salpetriere | |
| PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC | NCT06156891 | Oropharyngeal C... | Toxicities redu... Conventional tr... | 18 Years - 70 Years | Fudan University | |
| Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | NCT05777603 | Advanced Non Sm... | aerosolized azt... aerosolized van... pembrolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Combination of TATE and PD-1 Inhibitor in Liver Cancer | NCT03259867 | Hepatocellular ... Gastric Cancer | Nivolumab Injec... Trans-arterial ... | 18 Years - 80 Years | Teclison Ltd. | |
| Safety and Efficacy of RX-af01 Combined With PD-1 Antibody | NCT05576961 | Solid Tumor Immune Checkpoi... Intestinal Flor... | RX-af01 Mixed bacteria High dose RX-af... | 18 Years - | Sun Yat-sen University | |
| Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer | NCT05982301 | Gastric Cancer Chemotherapy Ef... Immune Checkpoi... | Sintilimab, pac... | 18 Years - | Fudan University | |
| Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE). | NCT03447483 | Solid Tumor | Patients starti... | 18 Years - | Institut Claudius Regaud | |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors | NCT05915481 | Advanced Solid ... Stereotactic Bo... Immune Checkpoi... Safety Efficacy | Cadonilimab Stereotactic bo... | 18 Years - 75 Years | Peking University Third Hospital | |
| Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 | NCT05222932 | Melanoma Head and Neck S... | TILT-123 Avelumab | 18 Years - | TILT Biotherapeutics Ltd. | |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | NCT03549000 | Non-small Cell ... Triple Negative... Pancreatic Duct... Colorectal Canc... Ovarian Cancer Renal Cell Carc... Metastatic Cast... | NZV930 PDR001 NIR178 | 18 Years - | Novartis | |
| A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC | NCT05698264 | Non Small Cell ... EGFR Gene Mutat... Immune Checkpoi... | concomitant TTF... concomitant TTF... | 18 Years - | Shaare Zedek Medical Center | |
| A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary | NCT06279104 | Ovarian Clear C... | physician's cho... immune checkpoi... | 18 Years - 75 Years | Tongji Hospital | |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | NCT03841110 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small Cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | FT500 Nivolumab Pembrolizumab Atezolizumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary | NCT06279104 | Ovarian Clear C... | physician's cho... immune checkpoi... | 18 Years - 75 Years | Tongji Hospital | |
| Combination of TATE and PD-1 Inhibitor in Liver Cancer | NCT03259867 | Hepatocellular ... Gastric Cancer | Nivolumab Injec... Trans-arterial ... | 18 Years - 80 Years | Teclison Ltd. | |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | NCT05846659 | Oligoprogressiv... | IMSA101 Immune checkpoi... PULSAR | 18 Years - | ImmuneSensor Therapeutics Inc. | |
| Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | NCT05777603 | Advanced Non Sm... | aerosolized azt... aerosolized van... pembrolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer | NCT05385185 | Leptomeningeal ... Immune Checkpoi... Endostatin | Camrelizumab or... | 18 Years - | Hebei Medical University | |
| Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) | NCT04968106 | Resectable Sarc... | Doxorubicin Ifosfamide INCMGA00012 | 18 Years - | Institut Bergonié | |
| Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer | NCT03506997 | Castration-resi... | Pembrolizumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Thyroid Dysfunction and Nivolumab Reponse in NSCLC | NCT04470440 | Non Small Cell ... Treatment Adver... Thyroid Dysfunc... Immune Checkpoi... Prognosis | 18 Years - | University Hospital, Brest | ||
| Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer. | NCT06227728 | Non Small Cell ... Breast Cancer Colorectal Canc... Gastric Cancer Liver Cancer Advanced Cancer Immune Checkpoi... | 18 Years - 80 Years | Gene Solutions | ||
| Priming Immunotherapy in Advanced Disease With Radiation | NCT03313804 | Non-small Cell ... Squamous Cell C... | Immune checkpoi... Radiation Thera... | 18 Years - | University of Kentucky | |
| ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI | NCT06388031 | Non-small Cell ... | Immune checkpoi... | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases | NCT04793737 | Metastatic Mela... | Precision Radia... | 18 Years - | Karolinska University Hospital | |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors | NCT05915481 | Advanced Solid ... Stereotactic Bo... Immune Checkpoi... Safety Efficacy | Cadonilimab Stereotactic bo... | 18 Years - 75 Years | Peking University Third Hospital | |
| Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors | NCT05799898 | Cancer Immune Checkpoi... Cardiovascular ... Immune-related ... | No intervention... | 18 Years - | Institut Mutualiste Montsouris | |
| Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer | NCT05982301 | Gastric Cancer Chemotherapy Ef... Immune Checkpoi... | Sintilimab, pac... | 18 Years - | Fudan University | |
| A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | NCT06255223 | Renal Cell Carc... Radiotherapy Immune Checkpoi... | High-dose Radio... Low-dose Radiot... Anti-PD-1 monoc... | 18 Years - 80 Years | Jinling Hospital, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
